Analytical Data
-
Gene name
Itm2a
- Application
-
Alternative Names
Protein E25
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q61500
-
Expression Region
1-263aa
-
Molecular Weight
31.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ITM2A (Integral Membrane Protein 2A) is a member of the integral membrane protein family, known for its role in various cellular processes including calcium signaling, cell differentiation, and immune responses. Recent studies have highlighted its potential impact in several diseases, including cancer and neurodegenerative disorders. The research into ITM2A recombinant proteins has gained momentum due to their possible applications in therapeutic interventions and as biomarkers. Scientists have been focused on elucidating the structure and function of ITM2A to understand its mechanism of action at the molecular level. Advances in recombinant DNA technology have facilitated the production of ITM2A in various expression systems, allowing researchers to obtain large quantities of purified proteins for functional and structural studies. These efforts aim to unravel the specific roles of ITM2A in pathophysiological contexts, paving the way for novel diagnostic and therapeutic strategies. Understanding the precise interactions and pathways involving ITM2A can lead to innovative treatments targeting diseases associated with its dysregulation. Overall, the exploration of ITM2A recombinant proteins represents a promising avenue in biomedical research with significant implications for future clinical applications.
